EP1261371A4 - Membrane estrogen receptor-directed therapy in breast cancer - Google Patents
Membrane estrogen receptor-directed therapy in breast cancerInfo
- Publication number
- EP1261371A4 EP1261371A4 EP01912991A EP01912991A EP1261371A4 EP 1261371 A4 EP1261371 A4 EP 1261371A4 EP 01912991 A EP01912991 A EP 01912991A EP 01912991 A EP01912991 A EP 01912991A EP 1261371 A4 EP1261371 A4 EP 1261371A4
- Authority
- EP
- European Patent Office
- Prior art keywords
- breast cancer
- estrogen receptor
- directed therapy
- membrane estrogen
- membrane
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
- C12N15/1138—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against receptors or cell surface proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2869—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against hormone receptors
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/31—Chemical structure of the backbone
- C12N2310/315—Phosphorothioates
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Genetics & Genomics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Biomedical Technology (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Molecular Biology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Biotechnology (AREA)
- Endocrinology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- General Engineering & Computer Science (AREA)
- Microbiology (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Neurology (AREA)
- Oncology (AREA)
- Reproductive Health (AREA)
- Cell Biology (AREA)
- Epidemiology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US18502600P | 2000-02-25 | 2000-02-25 | |
US185026P | 2000-02-25 | ||
PCT/US2001/005897 WO2001062288A1 (en) | 2000-02-25 | 2001-02-23 | Membrane estrogen receptor-directed therapy in breast cancer |
Publications (2)
Publication Number | Publication Date |
---|---|
EP1261371A1 EP1261371A1 (en) | 2002-12-04 |
EP1261371A4 true EP1261371A4 (en) | 2005-04-13 |
Family
ID=22679250
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP01912991A Withdrawn EP1261371A4 (en) | 2000-02-25 | 2001-02-23 | Membrane estrogen receptor-directed therapy in breast cancer |
Country Status (5)
Country | Link |
---|---|
EP (1) | EP1261371A4 (en) |
JP (1) | JP2003523404A (en) |
AU (2) | AU4171001A (en) |
CA (1) | CA2400874A1 (en) |
WO (1) | WO2001062288A1 (en) |
Families Citing this family (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1366366B1 (en) | 2000-05-10 | 2010-10-20 | Signe BioPharma Inc. | Compositions and methods for the diagnosis, treatment and prevention of steroid hormone responsive cancers |
EP1490502B1 (en) * | 2001-11-14 | 2013-01-09 | Signe BioPharma Inc. | Screening method for predicting susceptibility to breast cancer |
EP1499343A4 (en) * | 2002-03-28 | 2005-12-28 | Medvet Science Pty Ltd | A method of modulating cellular activity |
SE0401302D0 (en) * | 2004-05-21 | 2004-05-21 | Forskarpatent I Syd Ab | Inhibition of recognized phosphorylation |
FR2873699B1 (en) * | 2004-07-29 | 2009-08-21 | Pierre Fabre Medicament Sa | NOVEL ANTI-IGF ANTIBODIES IR RT USES THEREOF |
NZ599005A (en) * | 2009-08-24 | 2014-11-28 | Phigenix Inc | Targeting pax2 for the treatment of breast cancer |
US9487582B2 (en) * | 2010-01-08 | 2016-11-08 | Institut National De La Sante Et De La Recherche Medicale (Inserm) | Methods for treating pancreatic cancer |
US20220008636A1 (en) * | 2020-07-12 | 2022-01-13 | Henry J. Smith | Apheresis to remove interfering substances |
CN115369092A (en) * | 2022-09-30 | 2022-11-22 | 北京大学 | Quantitative screening method of estrogen receptor antagonist based on cell impedance sensing |
CN116284383B (en) * | 2023-03-01 | 2023-11-03 | 宜兴食品与生物技术研究院有限公司 | Method for rapidly obtaining 17 beta-estradiol murine IgG full-length antibody and Fab antibody |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2055441C (en) * | 1989-05-19 | 2003-01-07 | Robert M. Hudziak | Her2 extracellular domain |
US5183736A (en) * | 1990-03-30 | 1993-02-02 | La Jolla Cancer Research Foundation | Methods using estrogen receptor as a constitutive transcriptional activator and a repressor |
-
2001
- 2001-02-23 WO PCT/US2001/005897 patent/WO2001062288A1/en not_active Application Discontinuation
- 2001-02-23 EP EP01912991A patent/EP1261371A4/en not_active Withdrawn
- 2001-02-23 AU AU4171001A patent/AU4171001A/en active Pending
- 2001-02-23 JP JP2001561352A patent/JP2003523404A/en not_active Withdrawn
- 2001-02-23 AU AU2001241710A patent/AU2001241710B2/en not_active Ceased
- 2001-02-23 CA CA002400874A patent/CA2400874A1/en not_active Abandoned
Non-Patent Citations (6)
Title |
---|
ABBONDANZA CIRO ET AL: "Characterization and epitope mapping of a new panel of monoclonal antibodies to estradiol receptor", STEROIDS, vol. 58, no. 1, 1993, pages 4 - 12, XP001183746, ISSN: 0039-128X * |
KUNISUE H ET AL: "ANTI-HER2 ANTIBODY ENHANCES THE GROWTH INHIBITORY EFFECT OF ANTI-OESTROGEN ON BREAST CANCER CELLS EXPRESSING BOTH OESTROGEN RECEPTORS AND HER2", BRITISH JOURNAL OF CANCER, LONDON, GB, vol. 82, no. 1, January 2000 (2000-01-01), pages 46 - 51, XP001008510, ISSN: 0007-0920 * |
MOREY ANJALI K ET AL: "Estrogen and progesterone inhibit vascular smooth muscle proliferation", ENDOCRINOLOGY, vol. 138, no. 8, 1997, pages 3330 - 3339, XP002304840, ISSN: 0013-7227 * |
See also references of WO0162288A1 * |
SOMJEN DALIA ET AL: "Nongenomic effects of an anti-idiotypic antibody as an estrogen mimetic in female human and rat osteoblasts", JOURNAL OF CELLULAR BIOCHEMISTRY, vol. 65, no. 1, 1997, pages 53 - 66, XP002304841, ISSN: 0730-2312 * |
WITTERS LOIS M ET AL: "Enhanced anti-proliferative activity of the combination of tamoxifen plus HER-2-neu antibody", BREAST CANCER RESEARCH AND TREATMENT, vol. 42, no. 1, 1997, pages 1 - 5, XP002304672, ISSN: 0167-6806 * |
Also Published As
Publication number | Publication date |
---|---|
JP2003523404A (en) | 2003-08-05 |
CA2400874A1 (en) | 2001-08-30 |
AU2001241710B2 (en) | 2005-07-21 |
WO2001062288A1 (en) | 2001-08-30 |
AU4171001A (en) | 2001-09-03 |
EP1261371A1 (en) | 2002-12-04 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU2002215907A1 (en) | Massaging breast pump and funnel therefor | |
AU2002212527A1 (en) | Thermometry-based breast cancer risk assessment | |
GB0028429D0 (en) | Therapy | |
IL206604A0 (en) | Transmembrane protein expressed in prostate cancer | |
HUP0300005A3 (en) | Modified cytokines for use in cancer therapy | |
AU4171001A (en) | Membrane estrogen receptor-directed therapy in breast cancer | |
IL156690A0 (en) | Specific human antibodies for selective cancer therapy | |
AU2890199A (en) | Gata-3-expression in human breast carcinoma | |
GB0005257D0 (en) | Breast cancer hormonal therapy | |
HUP0300339A3 (en) | Use of fulvestrant in the treatment of resistant breast cancer | |
GB0002835D0 (en) | Drug resistance in cancer | |
IL161762A0 (en) | Estradiol inhibiting agents in breast cancer | |
AU2001288921A1 (en) | Human breast cancer biomarkers | |
AU2002215111A1 (en) | Ruthenium-aryl-compounds in cancer therapy | |
GB0026015D0 (en) | Cancer treatment | |
AU2001257325A1 (en) | Cancer treatment | |
HUP0301833A3 (en) | Crf2 ligands in combination therapy | |
AU2001236782A1 (en) | 34p3d7: a tissue specific protein highly expressed in prostate cancer | |
AU2001238144A1 (en) | 83p5g4: a tissue specific protein highly expressed in prostate cancer | |
IL151662A0 (en) | Atm mutations in breast cancer | |
AU2001257168A1 (en) | Cancer treatment | |
AU2001238697A1 (en) | Personal breast cancer indicator | |
GB0017620D0 (en) | Flavonoids in cancer treatment | |
TW417430U (en) | Massage divece in brassiere | |
GB0022216D0 (en) | Human FAP-a-specific antibodies for use in cancer therapy |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
17P | Request for examination filed |
Effective date: 20020925 |
|
AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE TR |
|
AX | Request for extension of the european patent |
Free format text: AL;LT;LV;MK;RO;SI |
|
RIC1 | Information provided on ipc code assigned before grant |
Ipc: 7A 61K 39/395 A Ipc: 7C 07K 14/72 B Ipc: 7A 61K 39/40 B Ipc: 7A 61K 39/42 B |
|
A4 | Supplementary search report drawn up and despatched |
Effective date: 20050225 |
|
RTI1 | Title (correction) |
Free format text: MEMBRANE ESTROGEN RECEPTOR-DIRECTED TREATMENT OF CANCER |
|
GRAP | Despatch of communication of intention to grant a patent |
Free format text: ORIGINAL CODE: EPIDOSNIGR1 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN |
|
18D | Application deemed to be withdrawn |
Effective date: 20070317 |